Vireo Health International (CSE: VREO) (OTC: VREOF) - Investor Dashboard


Vireo Health
CSE Ticker: VREO
OTC Ticker: VREOF
Sector: Health & Wellness
Industry: CPG
Country: U.S./Canada
Employees: > 300
Established: 2012
CEO: Kyle Kingsley, M.D.

Summary

Fiscal Year-End: Dec 31
Auditor: Davidson & Company LLP
Exchanges: CSE, OTC
Sector: Healthcare
State with Operations: 10
Headquarters: Minneapolis, MN

Financials (03/31/19)

Cash on hand: $40.4 million
Fixed Investment: $28.5 million
Shareholders’ Equity: $109.3 million
Revenues – Last Quarter: $5.8 million
Adj. Gross Margin : 36.6%
EPS : -$0.06

Capital Structure (5/30/19)

Last Financing: 12.1 million shares at US$4.25
As-converted Shares: 83.0 million
Warrants: 1.6 million
Options: 22.2 million
Diluted Shares: 107.8 million

 


Company Brief

Vireo Health International, Inc. (CSE: VREO) (OTC: VREOF) is an American leading science-focused, multi-state cannabis company. Upon the successful completion of five pending acquisitions, the Company will operate in 11 states — Minnesota, New York, Pennsylvania, Maryland, Ohio, Rhode Island, Arizona, Massachusetts, Nevada, New Mexico and Puerto Rico.

Vireo’s physician-led team of more than 300 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries.

Featured Video

Using Science to Enable Cannabis Substitution for Opioids, Tobacco and Alcohol.


Highlights

  • Vireo has a 10-state footprint, with early operations in Minnesota, where it is one of two providers, and New York, where it was one of the first five operators
  • Recently completed MA, NM, NV, and AZ acquisitions
  • Vireo’s retail outlets are being transformed and rebranded to “Green Goods” dispensaries
  • To date, successfully raised $113 million in debt and equity financing to support its multi-state operations and growth plans

Growth Strategy

  • Vireo intends to continue to expand its footprint into multiple new states through cost-effective and opportunistic strategies which involve participating in competitive application processes and acquiring existing licensees
  • The company has an LOI for an acquisition in California
  • Entered the industrial hemp market and holds two hemp licenses through its wholly-owned subsidiaries
  • Its extensive intellectual property portfolio has been developed to build a durable long-term business model that differs from peers

Differentiators

  • Focused on transformative intellectual property ranging from novel product formulations, to agricultural scale cannabinoid production processes and equipment
  • Vireo plans to leverage its medical, scientific and operational expertise to efficiently expand its operation in existing markets and enter new markets
  • The company is focused on prudent capital allocation and aims to enter new markets cost effectively

Vireo Timeline


Institutional Analyst Coverage

Graeme Kreindler, CPA, CA
Eight Capital

Matt Bottomley, CPA, CA, CBV
Canaccord Genuity Corp.


Curated Stories & News


Visit Vireo Health International, Inc.
at www.vireohealth.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Vireo Health International, Inc. is a client of NCV Media, LLC. Read our full disclaimer.